BGPartner advised Araris Biotech Ltd in a CHF 24 million financing round, involving the two co-lead investors 4BIO Capital and Pureos Bioventures.
Araris Biotech Ltd, a company pioneering antibody-drug conjugate (ADC) linker technology, intends to use the proceeds to support advancement of lead ADCs in preclinical and into clinical development.
The round was co-led by 4BIO Capital and Pureos Bioventures, with participation from new investors, including Wille AG and the Institute for Follicular Lymphoma Innovation. The round also included participation from existing investors VI Partners, Schroders Capital, btov Partners and Redalpine.
“We’re thrilled to have support from this group of investors who recognize the potential of our linker technology in this exciting and growing ADC field and look forward to using these proceeds to support our efforts in advancing our ADC candidates toward the clinic” said Philipp Spycher, Ph.D., chief executive officer at Araris Biotech Ltd.
The Araris Biotech Ltd press release can be found here:
BGPartner assisted Araris Biotech Ltd in the negotiations and advised on all Swiss legal matters regarding this financing round. The team was led by Oliver Gnehm (Partner) and further consisted of Thomas Gysin (Senior Associate).
More information about our negotiation expertise can be found here.
According to BILANZ Wirtschaftsmagazin and Le Temps BGPartner has been awarded four times in a row as top law firm in the area of “Private Equity and Venture Capital”. Click here for the complete ranking.